Follow the people · Insider

MW

Matthew Wein

Insider · Officer · MGX

Matthew Wein files insider transactions with the SEC as an officer of Metagenomi. We hold 3 disclosed purchases and sales filed since 3 April 2024, 1 of them in the last 90 days.

  • Files forMGX
  • Disclosed buys and sells3 in all, 1 in the last 90 days
  • Last disclosure10 September 2026

Positions held

1 post we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 1 April 20248 September 2026Officer · Metagenomi 17 Form 4 lines · source: SEC Form 4

Every transaction

17 transactions from SEC Form 4 — one row each, sort any column, open a row for the filing
17 of 17 shown
8 Sep 202610 Sep 2026SEC Form 42 dsold on the open marketMetagenomi Therapeutics358 sharesup +0.0%up +0.0%
5 Jun 202610 Jun 2026SEC Form 45 dsold on the open marketMetagenomi Therapeutics558 sharesdown −9.4%down −5.7%
1 Apr 20263 Apr 2026SEC Form 42 dwas grantednot a tradeMetagenomi Therapeutics11,000 sharesdown −13.4%down −14.1%
1 Apr 20263 Apr 2026SEC Form 42 dwas grantednot a tradeMetagenomi Therapeuticsderivative68,000 sharesdown −13.4%down −14.1%
5 Mar 20269 Mar 2026SEC Form 44 dsold on the open marketMetagenomi Therapeutics482 sharesdown −28.0%down −27.5%
5 Mar 20269 Mar 2026SEC Form 44 dsold on the open marketMetagenomi Therapeutics482 sharesdown −28.0%down −27.5%
5 Dec 20258 Dec 2025SEC Form 43 dsold on the open marketMetagenomi199 sharesdown −34.8%down −35.9%
1 Dec 20251 Dec 2025SEC Form 40 dwas grantednot a tradeMetagenomi96,000 sharesdown −27.5%down −27.5%
5 Sep 20251 Dec 2025SEC Form 487 dsold on the open marketMetagenomi199 sharesdown −39.3%down −27.5%
6 Jun 20259 Jun 2025SEC Form 43 dsold on the open marketMetagenomi199 sharesdown −32.9%down −30.5%
1 Apr 20253 Apr 2025SEC Form 42 dwas grantednot a tradeMetagenomiderivative21,875 sharesdown −12.1%down −7.9%
1 Apr 20253 Apr 2025SEC Form 42 dwas grantednot a tradeMetagenomiderivative22,725 sharesdown −12.1%down −7.9%
1 Apr 20253 Apr 2025SEC Form 42 dwas grantednot a tradeMetagenomi3,650 sharesdown −12.1%down −7.9%
1 Apr 20253 Apr 2025SEC Form 42 dwas grantednot a tradeMetagenomi3,775 sharesdown −12.1%down −7.9%
5 Mar 20257 Mar 2025SEC Form 42 dsold on the open marketMetagenomi930 sharesdown −40.5%down −44.0%
1 Apr 20243 Apr 2024SEC Form 42 dwas grantednot a tradeMetagenomiderivative43,717 sharesdown −89.3%down −88.9%
1 Apr 20243 Apr 2024SEC Form 42 dwas grantednot a tradeMetagenomi10,397 sharesdown −89.3%down −88.9%

Both percentages are the stock’s move, not Matthew Wein’s return: a disclosure gives a band, never an amount, so nobody can say how much was bought or what it made. They run to the last close we hold11 Sep 2026, except where a name has since delisted, when the row names its own last session. We publish no close, no volume and no dollar figure behind them. 17 of the 17 rows shown carry a percentage; the rest are dashes with the reason on the row.

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.

Some filings reach us as photographs of paper rather than as a form we can read as text. Those are shown here only once they have been read and checked, so this page can hold fewer lines than the filings behind it contain. The link on every row opens the original document, which is always the full record.